United Immunity enters into the Research Collaboration Agreement with AstraZeneca

July 26th, 2024 | Press Release

United Immunity (Tokyo, Japan) enters into the Research Collaboration Agreement with AstraZeneca.
United Immunity develops its proprietary active targeting pullulan lipid nanoparticle (LNP) selective to myeloid cells as its Myeloid Targeting Platform^TM

PDF (Japanese)

Back to Press releases

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.